Used in the treatment of various cancers, particularly non-small cell lung cancer and other solid tumors, by blocking the PD-L1 protein on tumor cells. This inhibition prevents the interaction between PD-L1 and PD-1 receptors on T cells, thereby enhancing the immune system’s ability to recognize and destroy cancer cells. It is employed as an immune checkpoint inhibitor in immunotherapy regimens, often in patients with high PD-L1 expression. Currently under clinical investigation for efficacy in multiple advanced or metastatic cancers, showing potential for durable responses and improved survival outcomes.